These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35630083)

  • 1. Sorafenib in Metastatic Papillary Thyroid Carcinoma with
    Caterino M; Pirozzi M; Facchini S; Zotta A; Sica A; Lo Giudice G; Rauso R; Varriale E; Ciardiello F; Fasano M
    Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
    Alzahrani AS; AlQaraawi A; Al Sohaibani F; Almanea H; Abalkhail H
    Thyroid; 2012 May; 22(5):536-41. PubMed ID: 22435913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
    Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
    Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
    Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired Secondary RAS Mutation in BRAF
    Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC
    Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
    Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
    Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorafenib: key lessons from over 10 years of experience.
    Escudier B; Worden F; Kudo M
    Expert Rev Anticancer Ther; 2019 Feb; 19(2):177-189. PubMed ID: 30575405
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
    Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
    Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J; Liang J; Zhao T; Lin Y
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
    Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
    Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer.
    Danilovic DLS; Castro G; Roitberg FSR; Vanderlei FAB; Bonani FA; Freitas RMC; Coura-Filho GB; Camargo RY; Kulcsar MA; Marui S; Hoff AO
    Arch Endocrinol Metab; 2018 Jun; 62(3):370-375. PubMed ID: 29791660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The frequency of mutations in advanced thyroid cancer in Japan: a single-center study.
    Toda S; Iwasaki H; Okubo Y; Hayashi H; Kadoya M; Takahashi H; Yokose T; Hiroshima Y; Masudo K
    Endocr J; 2024 Jan; 71(1):31-37. PubMed ID: 38044137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation.
    Afkhami M; Karunamurthy A; Chiosea S; Nikiforova MN; Seethala R; Nikiforov YE; Coyne C
    Thyroid; 2016 Feb; 26(2):242-7. PubMed ID: 26422023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The discovery and development of sorafenib for the treatment of thyroid cancer.
    White PT; Cohen MS
    Expert Opin Drug Discov; 2015 Apr; 10(4):427-39. PubMed ID: 25662396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology.
    Soe MH; Chiang JM; Flavell RR; Khanafshar E; Mendoza L; Kang H; Liu C
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3206-e3216. PubMed ID: 35556126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.
    Casadei Gardini A; Chiadini E; Faloppi L; Marisi G; Delmonte A; Scartozzi M; Loretelli C; Lucchesi A; Oboldi D; Dubini A; Frassineti GL; Ulivi P
    BMC Cancer; 2016 Jul; 16():429. PubMed ID: 27388325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case of aggressive metastatic follicular variant papillary thyroid carcinoma with BRAF K601E and BCORL1 mutations.
    Attia D; Lurie A; Zhai Q; Mesko T; Smallridge R
    BMJ Case Rep; 2020 Jun; 13(6):. PubMed ID: 32606114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
    Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ
    Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk Stratification Using a Novel Genetic Classifier Including
    Jung CK; Jung SH; Jeon S; Jeong YM; Kim Y; Lee S; Bae JS; Chung YJ
    Thyroid; 2020 Nov; 30(11):1589-1600. PubMed ID: 32326836
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.